PF-08052667

PF-08052667 is an investigational biologic drug being developed for the treatment of non-muscle invasive bladder cancer (NMIBC), particularly in patients whose cancer has not responded to standard treatments such as Bacillus Calmette-Guérin (BCG) therapy. It is evaluated as both a monotherapy and in combination with BCG and/or sasanlimab (an anti-PD-1 antibody) in current clinical studies. PF-08052667 is administered via intravesical instillation (directly into the bladder)[1][2][3][5][7][15][17]. Early public clinical development suggests it is an antibody-based biologic, with the synonym SGN-B6N indicating potential targeting of a tumor-associated antigen in bladder cancer, possibly B7-H3, though the precise molecular target and mechanism of action are not fully disclosed in available trial records.

Other names

SGN-B6NSGN-B-6NSGN-B 6N